Publication:
Comparison of survival results of patients with t0 and t1-2-3 in pathological t staging in patients with non-small cell lung cancer who underwent surgery after neoadjuvant treatment

dc.contributor.authorKermenli, Tayfun
dc.contributor.authorMelek, Hüseyin
dc.contributor.authorBayram, Ahmet Sami
dc.contributor.authorGebitekin, Cengiz
dc.contributor.buuauthorMELEK, HÜSEYİN
dc.contributor.buuauthorBAYRAM, AHMET SAMİ
dc.contributor.buuauthorGEBİTEKİN, CENGİZ
dc.contributor.departmentTıp Fakültesi
dc.contributor.orcid0000-0003-0684-0900
dc.contributor.orcid0000-0003-1822-8153
dc.contributor.researcheridAAE-1069-2022
dc.contributor.researcheridAAI-5039-2021
dc.contributor.researcheridJCE-0097-2023
dc.contributor.researcheridABB-7580-2020
dc.date.accessioned2024-07-04T07:06:59Z
dc.date.available2024-07-04T07:06:59Z
dc.date.issued2020-01-01
dc.description.abstractAim: In this study, we aimed to compare the survival results of patients who underwent neoadjuvant treatment with NSCLC between March 1997 and August 2014 and were found to have T0N0 and T1-2-3/N0.Material and methods: A hundred ninety-five patients who had complete neoadjuvant therapy, complete lung resection and lymph node dissection, and pathologically diagnosed as T0 or T1-2-3/N0, M0 were included in the study.Results: Of the 195 patients included in the study, 181 were male, 14 were female and the mean age of the patients was 57.9. The mean age of the groups was as follows: group 1: 58.1, group 2: 57.7, group 3: 59.7 and group 4: 56.8. In our series the most common complication was atelectasis (n = 19). Others were prolonged air leak (n = 16), pneumonia (n = 12), apical pleural space (n = 6), wound infection (n = 3), cardiac problems (n = 3), hematoma (n = 3), bronchopleural fistula (n = 3), empyema (n = 2), chylothorax (n = 1). The 5-year survival rate for patients in the T0N0 group was 76.3%. This rate was 71.8% in group 2, 63.6% in group 3 and 44.1% in group 4.Conclusions: Survival was found to be better in patients who underwent surgery after neoadjuvant therapy and had a complete pathological response. We believe that we can provide better results with the increase in the number of cases detected as TxN0 after the neoadjuvant treatment and prolongation of the follow-up period.
dc.identifier.doi10.5114/kitp.2020.97252
dc.identifier.endpage51
dc.identifier.issn1731-5530
dc.identifier.issn1897-4252
dc.identifier.issue2
dc.identifier.startpage47
dc.identifier.urihttps://doi.org/10.5114/kitp.2020.97252
dc.identifier.urihttps://hdl.handle.net/11452/42867
dc.identifier.volume17
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherTermedia Publishing House
dc.relation.journalKardiochirurgia I Torakochirurgia Polska-Polish Journal of Thoracic and Cardiovascular Surgery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.subjectSurgical resection
dc.subjectSleeve resection
dc.subjectChemotherapy
dc.subjectTherapy
dc.subjectRadiotherapy
dc.subjectManagement
dc.subjectMortality
dc.subjectLobectomy
dc.subjectSuperior
dc.subjectRisk
dc.subjectNon-small cell lung cancer
dc.subjectNeoadjuvant treatment
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectSurgery
dc.titleComparison of survival results of patients with t0 and t1-2-3 in pathological t staging in patients with non-small cell lung cancer who underwent surgery after neoadjuvant treatment
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi
relation.isAuthorOfPublicationa600fc7e-754b-4a62-957d-5139e02d21ca
relation.isAuthorOfPublicationbdb7801d-f0bc-4abc-af2c-5bf7df23fbd5
relation.isAuthorOfPublication029ec57f-2451-4282-8110-61c87cd6a41d
relation.isAuthorOfPublication.latestForDiscoverya600fc7e-754b-4a62-957d-5139e02d21ca

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Melek_vd_2020.pdf
Size:
131.4 KB
Format:
Adobe Portable Document Format

Collections